Quick Answer
Xenon Pharmaceuticals Inc. reported Cash And Cash Equivalents At Carrying Value of $199.16 million for the year ending 2025.
- Xenon Pharmaceuticals Inc. showed an increase of +39.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: $43.61 million | Q1 2014: $34.95 million | Q2 2014: $35.09 million | Q3 2014: $33.73 million | Q1 2015: $65.92 million | Q2 2015: $64.35 million | Q3 2015: $65.47 million | Q1 2016: $56.06 million | Q2 2016: $35.21 million | Q3 2016: $54.14 million | Q1 2017: $20.16 million | Q2 2017: $23.09 million | Q3 2017: $14.69 million | Q4 2017: $20.49 million | Q1 2018: $17.20 million | Q2 2018: $47.44 million | Q3 2018: $87.96 million | Q1 2019: $52.18 million | Q2 2019: $37.08 million | Q3 2019: $37.67 million | Q2 2020: $44.20 million | Q3 2020: $15.10 million | Q1 2021: $87.99 million | Q2 2021: $82.93 million | Q3 2021: $87.81 million | Q1 2022: $116.54 million | Q2 2022: $369.99 million | Q3 2022: $103.49 million | Q1 2023: $69.51 million | Q2 2023: $64.55 million | Q3 2023: $99.57 million | Q1 2024: $58.90 million | Q2 2024: $136.73 million | Q3 2024: $87.62 million | Q1 2025: $116.66 million | Q2 2025: $135.38 million | Q3 2025: $104.51 million.
- Over the full 15 years of available data (2011 to 2025), Xenon Pharmaceuticals Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,329.9%.
- Historical annual values: Fiscal year 2025: $199.16 million | Fiscal year 2024: $142.71 million | Fiscal year 2023: $148.64 million | Fiscal year 2022: $57.24 million | Fiscal year 2021: $175.69 million | Fiscal year 2020: $45.01 million | Fiscal year 2019: $24.76 million | Fiscal year 2018: $67.75 million | Fiscal year 2017: $20.49 million | Fiscal year 2016: $17.10 million | Fiscal year 2015: $58.65 million | Fiscal year 2014: $72.03 million | Fiscal year 2013: $37.95 million | Fiscal year 2012: $60.16 million | Fiscal year 2011: $13.93 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: